Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722560 | 0.80 | RAB9A (0.59) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL17397927 | 0.80 | PLA2G7 (0.49) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL28800058 | 0.79 | PLA2G7 (0.46) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL6833454 | 0.78 | RAB9A (0.57) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| Bromide SCHEMBL7502411 | 0.78 | RAB9A (0.57) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL14881017 | 0.77 | MEN1 (0.54) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL3053636 | 0.77 | SYK (0.54) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL2981886 | 0.77 | ALDH1A1 (0.61) | PLA2G7ALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL899534 | 0.77 | SMN1; SMN2 (0.61) | PLA2G7ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5762561 | 0.77 | PLA2G7 (0.58) | PLA2G7ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | claimed |
| EP-2760856-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | claimed |
| EP-2760843-A2 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | claimed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | claimed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | claimed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | claimed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | claimed |
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2760843-A2 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | PLA2G7 1497/4885ALDH1A1 1942/4885TDP1 1848/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | PLA2G7 1497/4885ALDH1A1 1942/4885TDP1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.